Akebia Therapeutics Inc (AKBA)

[historyperson]

I've accumulated a few hundred shares since finding out about Akebia earlier this year. This could be my next big investment after AUPH is bought out or I sell at $40.

But one question, should I be worried about Auryxia revenue at all? "Net Product Revenue for Auryxia® (ferric citrate) Increases to $33.0 Million, Up 7.4% from Q2'FY20"

That doesn't seem like great growth for a relatively new drug a year after a terrible (covid) quarter...

Or is it all about the future of Vadadustat?

Thank you. Rooting for AKBA and hoping to continue to add below $4.